share_log

醫渡科技：截至2024年3月31日止財政年度的年度業績公告

YIDU TECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE FISCAL YEAR ENDED 31 MARCH 2024

Hong Kong Stock Exchange ·  Jun 27 00:07
Summary by Moomoo AI
医渡科技有限公司宣佈截至2024年3月31日止財政年度的年度業績。本集團收入微增0.3%，達807,076萬人民幣，毛利增長23.6%至339,445萬人民幣。年度虧損顯著減少65.0%，至221,242萬人民幣。大數據平台和解決方案收入增長41.4%，生命科學解決方案增長28.1%，而健康管理平台和解決方案收入下降48.7%。董事會不建議分派末期股息。公司繼續投資於AI技術，並在MedBench評測中的大語言模型獲得優異成績。截至報告期間，公司現金及現金等價物、定期存款等總額為3,409.9百萬元，與去年同期相近。公司將繼續聚焦核心業務，提升經營效率和盈利質量。
医渡科技有限公司宣佈截至2024年3月31日止財政年度的年度業績。本集團收入微增0.3%，達807,076萬人民幣，毛利增長23.6%至339,445萬人民幣。年度虧損顯著減少65.0%，至221,242萬人民幣。大數據平台和解決方案收入增長41.4%，生命科學解決方案增長28.1%，而健康管理平台和解決方案收入下降48.7%。董事會不建議分派末期股息。公司繼續投資於AI技術，並在MedBench評測中的大語言模型獲得優異成績。截至報告期間，公司現金及現金等價物、定期存款等總額為3,409.9百萬元，與去年同期相近。公司將繼續聚焦核心業務，提升經營效率和盈利質量。
Medi-Run Technology Co., Ltd. announced its annual performance for the fiscal year ending on March 31, 2024. The company's revenue increased slightly by 0.3% to RMB 8,070.76 million, and gross profit increased by 23.6% to RMB 3,394.45 million. The annual loss significantly decreased by 65.0% to RMB 2,212.42 million. Revenue from big data platforms and solutions increased by 41.4%, life science solutions increased by 28.1%, while revenue from health management platforms and solutions decreased by 48.7%. The board of directors does not recommend the distribution of final dividends. The company continues to invest in AI technology and has achieved excellent results in the MedBench evaluation of large language models. As of the reporting period, the company's total cash and cash equivalents, fixed deposits, etc. amounted to RMB 3,409.9 million, which is similar to the same period last year. The company will continue to focus on core business, improve operational efficiency and profit quality.
Medi-Run Technology Co., Ltd. announced its annual performance for the fiscal year ending on March 31, 2024. The company's revenue increased slightly by 0.3% to RMB 8,070.76 million, and gross profit increased by 23.6% to RMB 3,394.45 million. The annual loss significantly decreased by 65.0% to RMB 2,212.42 million. Revenue from big data platforms and solutions increased by 41.4%, life science solutions increased by 28.1%, while revenue from health management platforms and solutions decreased by 48.7%. The board of directors does not recommend the distribution of final dividends. The company continues to invest in AI technology and has achieved excellent results in the MedBench evaluation of large language models. As of the reporting period, the company's total cash and cash equivalents, fixed deposits, etc. amounted to RMB 3,409.9 million, which is similar to the same period last year. The company will continue to focus on core business, improve operational efficiency and profit quality.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more